89bio, Inc.

Industry · 7 registered clinical trials — 2 currently recruiting.

Status	Trial	Phase	Started
Recruiting	A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis	Phase 3	2024-05-24
Recruiting	A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-F Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis	Phase 3	2024-03-13
Active Not Recruiting	To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia Severe Hypertriglyceridemia	Phase 3	2023-06-15
Completed	PK Study of Liquid Formulation of BIO89-100 in Subjects With NASH With Compensation Cirrhosis NASH - Nonalcoholic Steatohepatitis	Phase 1	2021-08-16
Completed	Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoh NASH - Nonalcoholic Steatohepatitis	Phase 2	2021-06-04
Completed	Study to Explore the Efficacy and Safety of BIO89-100 (Pegozafermin) in Participants With Severe Hypertriglyce Severe Hypertriglyceridemia	Phase 2	2020-09-01
Completed	A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepat NASH	Phase 1 / Phase 2	2019-07-29